Institute of Oncology Research (IOR),
affiliated to USI,
run by an
independent
foundation with the same name
The Swiss Innovation Agency, Innosuisse, aims to promote science-based innovation in the interest of the economy and society in Switzerland.
|
Grantee: |
Andrea Alimonti |
|
Duration: |
12.2020 (18 months) |
|
Title: |
Development of a senolytic of natural origin for anti-aging therapy |
|
Acronym/ID: |
46608.1 IP-LS |
We have identified a promising molecule, of natural origin, characterized by anti-aging properties. With this project, we will perform in vitro and in vivo experiments necessary for the development of an innovative anti-aging therapeutic intervention.
|
Grantee: |
Andrea Alimonti |
|
Duration: |
11.2022 (18 months) |
|
Title: |
Development of a senolytic of natural origin for antiaging therapy |
|
Acronym/ID: |
103.496 IP-LS |
We have identified a natural extract characterized by anti-aging properties, as well as the active ingredient responsible for its action. With this project, we will perform the experiments necessary for the development of innovative anti-aging nutraceutical supplements.
|
Grantee: |
Francesco Bertoni |
|
Duration: |
08.2021 – 12.2023 |
|
Title: |
Evaluation of non-ATP competitive PI3Kδ inhibition with IOA-244 in the treatment of lymphoma |
|
Acronym/ID: |
55179.1 IP-LS |
Inhibition of PI3Kδ is an established modality for the treatment of lymphoma. The proposed project will deliver mechanistic and efficacy information on iOnctura’s PI3Kδ inhibitor IOA-244, which has a novel mechanism of target inhibition.
IOR
An institute affiliated to USI, run by an independent foundation
